For the quarter ending 2025-09-30, PMVP had -$7,790K decrease in cash & cash equivalents over the period. -$19,819K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,059 | -38,646 |
| Stock-based compensation expense | 1,383 | 3,176 |
| Depreciation | 31 | 69 |
| Accretion of discounts on marketable securities | 694 | 1,564 |
| Non-cash lease income | 3 | 4 |
| Loss on sales and disposals of fixed assets, net | 1 | -38 |
| Other, net | -1 | 16 |
| Prepaid expenses and other assets | 162 | -3,167 |
| Accounts payable | 801 | -3,981 |
| Accrued expenses | -117 | 1,193 |
| Net cash used in operating activities | -19,820 | -36,568 |
| Purchases of property and equipment | -1 | 15 |
| Proceeds from sale of property and equipment | 1 | 30 |
| Purchases of marketable securities | 20,473 | 46,689 |
| Maturities of marketable securities | 32,499 | 86,374 |
| Net cash provided (used) by investing activities | 12,028 | 39,700 |
| Proceeds from the exercise of stock options and common stock issued under the 2020 eip | 0 | 113 |
| Net cash provided by financing activities | 0 | 113 |
| Impact of exchange rates on cash, cash equivalents, and restricted cash | 2 | 6 |
| Net increase (decrease) in cash and cash equivalents | -7,790 | 3,251 |
| Cash and cash equivalents at beginning of period | 40,876 | - |
| Cash and cash equivalents at end of period | 36,337 | - |
PMV Pharmaceuticals, Inc. (PMVP)
PMV Pharmaceuticals, Inc. (PMVP)